```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, represents a valuable research reagent extensively employed in platelet research . This antibody fragment selectively targets the glycoprotein IIb/IIIa receptor on platelets , blocking platelet aggregation . As a result, it's commonly investigated as a technique to explore the pathways underlying coagulation and to determine the effectiveness of antiplatelet therapies. Supply is typically get more info restricted to institutional settings.
```
The Abciximab Compound Research: Utilizing C7E3 and Compound 143653-53-6 in Scientific Assessments
Ongoing research into abciximab, a platelet aggregation inhibitor, frequently incorporates the monoclonal antigen C7E3 and the substance identified as 143653-53-6. These reagents are essential for investigating abciximab's mechanism of action, assessing its effectiveness in different patient populations, and understanding potential predictors of therapeutic success. Further study leveraging these particular reagents is expected to generate valuable information for optimizing therapeutic strategies concerning cardiovascular conditions.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Exploring Research Avenues with Abciximab 143653-53-6 and C7E3
Recent studies indicate that Abciximab (identified as 143653-53-6) holds significant research potential, particularly when combined with a C7E3 construct. Preliminary observations indicated that this combination could improve patient outcomes in various heart-related settings. Further exploration is centered on elucidating the specific mode of effect between Abciximab and C7E3, including assessment of platelet clumping and vascular safeguarding.
- Future study work intend to maximize dosing strategies.
- Laboratory systems are were applied to further confirm the propositions.
- Clinical assessments will be essential to completely assess clinical effectiveness.
```
Abciximab (C7E3) for Research: Quality and Characteristics (143653-53-6)
Researchers requiring C7E3 for in vitro investigations should rigorously evaluate integrity and documented characteristics. The compound is typically supplied as a lyophilized powder and comprehensive analytical documentation including assessment by HPLC , binding affinity assays, and bacterial endotoxin testing are available. Confirm the supplier's certificate of analysis clearly states defined ranges for related substances and conforms to all quality assurance guidelines.
Pharmaceutical-Grade C7E3 Details & Supply
Acquiring research-grade Abciximab, specifically referencing the compound C7E3 and identified by the product number 143653-53-6, requires careful consideration of its source . This antibody is frequently utilized in cell-based studies , particularly those involving platelet adhesion and clotting . Existing vendors offer this substance in varying quantities , typically ranging from g to substantial bulk amounts . Kindly advise reviewing the documentation of testing to verify purity and appropriateness for your specific application . Moreover, ensure the expiration date before procuring to maintain maximum effectiveness.
- Common Purity: >95%
- Preservation Conditions: -20°C in appropriate conditions
- Intended Purpose: Platelet Adhesion Suppression Studies